Top Tweets for #FuM
#FUM 🔥📈💪👌👀
Futura Medical plc has announced positive results from an additional Home User Test for its new Eroxon® "Intense" formula, slated for a first-half 2027 commercialisation. The test, involving 115 men with mild to moderate erectile dysfunction, showed significant improvements over the original Intense presentation and current Eroxon® formulation. Participants reported satisfaction with erection hardness in 82% of encounters, up from 71% for the original Intense, and erections lasting long enough for intercourse in 87% of encounters. The clinically validated IIEF-EF scale demonstrated a 7.86-point improvement from baseline, exceeding the clinically meaningful threshold and particularly pronounced in men with moderate ED, where 87% achieved a meaningful improvement. User satisfaction and purchase intent also improved, reinforcing the potential of the optimised Intense presentation to offer a differentiated consumer experience.
https://t.co/Sqy1p0Bbjh
✅ Futura Medical (#FUM $FUM.L): "Results demonstrated that the optimised presentation improved performance across all key measures compared with both the original Intense presentation and the current Eroxon® formulation."
Weekend podcast covering #FORG #RKH #TRP #RCGH #REV #SRVL #FUM #KOO #EME #EST #IQE #ACRM #ECOB #TGA
@ForgentPlc @TowerResources @RC365plc @Rev_plc @ServalResources @EmpyreanEnergy @EastStar_PLC @Acuity_RM @ECOBPLC
https://t.co/h2SmvHKq6m
Weekend podcast covering #FORG #RKH #TRP #RCGH #REV #SRVL #FUM #KOO #EME #EST #IQE #ACRM #ECOB #TGA
@ForgentPlc @TowerResources @RC365plc @Rev_plc @ServalResources @EmpyreanEnergy @EastStar_PLC @Acuity_RM @ECOBPLC
https://t.co/h2SmvHKq6m
#FUM
Firming up 📈
Long way to go …
Needs to do almost x20 to get to last 12 month level
#FUM
Let the offers roll in for a SALE Surely valued in multiples of today’s price
Company with product generating revenue and another with FDA approval due Q4
What’s not to like at this value 📈
Cash resources also into February 2027 which would allow the Company to explore an M&A and Formal Sale Process
Taking this into account, together with the commercial and development milestones achieved in recent months which have reduced uncertainty surrounding the business, the Company's current market valuation does not, in the opinion of the board of directors (the "Board"), adequately reflect the strategic value and commercial potential of its portfolio.
In particular, WSD4000 represents a highly attractive strategic opportunity.
Based on published epidemiology studies and consequent numbers of potential users in selected key international markets, the Company estimates potential peak annual consumer sales of WSD4000 in excess of US$400 million, compared to over US$250 million for Eroxon® and Eroxon® Intense combined. That estimate is further supported by independently developed, risk-adjusted, commercial modelling indicating the potential for annual consumer sales of WSD4000 of approximately US$445-470 million across key international markets, underlining the significant unmet need for effective female sexual health products and the scalability of the Company's platform technology1.
The Board believes that the Company's portfolio could attract interest from strategic parties able to leverage established commercial capabilities, broader distribution networks, complementary product portfolios or operational scale, thereby creating the potential to unlock additional value beyond that achievable by the Company as a standalone business.
Accordingly, and given the Company's limited cash resources, the Board believes that it is now in the best interests of shareholders to explore a range of strategic alternatives with the objective of maximising shareholder value. These alternatives include the potential sale of one or more of the Company's assets and licensing or other commercial arrangements (the "M&A Process"), and the potential sale of the Company as a whole. The Company has therefore decided to commence a formal sale process in accordance with Note 2 on Rule 2.6 of the Takeover Code (the "Formal Sale Process").
#FUM
Starting to fire up 📈 £3.5m market cap and £2m+ in cash
The offer should be in the x5 x10 for what they have 👇 management would be looking for minimum
Fundraise + Launch of M&A and Formal Sale Process
Taking this into account, together with the commercial and development milestones achieved in recent months which have reduced uncertainty surrounding the business, the Company's current market valuation does not, in the opinion of the board of directors (the "Board"), adequately reflect the strategic value and commercial potential of its portfolio.
In particular, WSD4000 represents a highly attractive strategic opportunity. Based on published epidemiology studies and consequent numbers of potential users in selected key international markets, the Company estimates potential peak annual consumer sales of WSD4000 in excess of US$400 million, compared to over US$250 million for Eroxon® and Eroxon® Intense combined. That estimate is further supported by independently developed, risk-adjusted, commercial modelling indicating the potential for annual consumer sales of WSD4000 of approximately US$445-470 million across key international markets, underlining the significant unmet need for effective female sexual health products and the scalability of the Company's platform technology
The Board believes that the Company's portfolio could attract interest from strategic parties able to leverage established commercial capabilities, broader distribution networks, complementary product portfolios or operational scale, thereby creating the potential to unlock additional value beyond that achievable by the Company as a standalone business.
#FUM
Tracarta Ltd, through Fiske Nominees Limited, has acquired a significant stake in Futura Medical Plc, crossing a notification threshold on September 25, 2026. The notification reveals that Tracarta Ltd now holds 3.96% of voting rights attached to shares and an additional 0.34% through financial instruments, specifically warrants with an expiration date of September 25, 2031, resulting in a total holding of 4.3% of voting rights. This acquisition represents a change in the breakdown of voting rights for Futura Medical Plc
https://t.co/HfolRBhJNt
#FUM
Philip J Milton & Company Plc has acquired a new holding in Futura Medical PLC, crossing a notification threshold on September 14, 2026. The firm now holds 4.46% of the voting rights, representing 28,511,683 shares, with no voting rights held through financial instruments. This notification was made to the issuer on September 16, 2026.
https://t.co/eRx51281wO
Tranquils. La privatització d’aquest espai i els renders és només propaganda. Igual de l’anunciada fa més d’un any biblioteca Parc de les Arts, la reforma de la plaça Enric Granados anunciada al 2019 o els espais gastronòmics del Mercat del Pla q obrien al juny del 2019 #fum
🏊Vivid Arquitectura guanya el concurs d’idees de l'antiga estació d’autobusos i transformarà el Centre Històric amb nous espais esportius, comercials i per a la ciutadania.
🗣️Larrosa: es guanya “un extraordinari equipament pel centre de la ciutat”
+https://t.co/8s8cKUrQxk
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
118.9M followers
Cristiano Ronaldo
@cristiano
114.6M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90.1M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.5M followers
Virat Kohli
@imvkohli
73.5M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.5M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers